Director/PDMR Shareholding

RNS Number : 5516U

Evocutis PLC

23 December 2011

 



Press Release

23 December 2011

Evocutis plc

("the Company")

Director's Dealing

Evocutis plc (AIM:EVO), the speciality pharmaceutical research and development company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, has today been notified that, on 22 December 2011, Tom Bannatyne, Chairman of the Company, acquired 750,000 ordinary shares of 1p each in the Company, at a price of 2.625p per share. Following this purchase Mr Bannatyne has a beneficial interest in 14,714,670 ordinary shares representing approximately 8.50 per cent. of the Company's issued share capital.

- Ends -

For further information, please contact:

Evocutis plc
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman
Zeus Capital ltd
Tom Rowley/Andrew Jones	Tel: [phone]
	www.zeuscapital.co.uk

XCAP Securities plc
Karen Kelly/John Grant	Tel: [phone]
	www.xcapgroup.co.uk

Media enquiries:

Abchurch Communications
Adam Michael/ Jamie Hooper	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

About Evocutis plc

With a rich portfolio of new product opportunities Evocutis offers antimicrobial expertise to the cosmetic, consumer healthcare and pharmaceutical industries.

Additionally, Evocutis is uniquely able to combine research for laboratory testing, advanced skin models and clinical testing to offer a complete service for the development of skin care products and ingredients. Through research and testing we enable our clients to advance the discovery of skin care products that actually work.

Evocutis works with companies at all stages of the product development pipeline offering R&D solutions from ownable technology platforms through to tailored research, and now provides an independent commercial testing facility to the pharmaceutical and healthcare industries. Unique characteristics of its colonised full thickness model of human skin (LabSkin^TM) allow rapid, cost effective screening of, for example, anti-aging, anti-inflammatory and antimicrobial ingredients and products for use on skin.

Evocutis also offers high quality contract research services specialising in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research.

When it comes to topical antimicrobial innovation the Evocutis focus is simple: intelligent and specialised R&D input. 

For further information, please see www.evocutis.com.

 

END

 

 

RDSPGGUCPUPGPGP